Search results for "B-cell antigen"

showing 1 items of 1 documents

Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and…

2020

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non-Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old …

Oncologyperipheral t-cell lymphomamedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryPeripheral T-cell lymphoma not otherwise specifiedCase ReportSettore MED/08 - Anatomia Patologicarituximab.03 medical and health sciences0302 clinical medicinerituximabimmune system diseasesInternal medicinehemic and lymphatic diseasesMedicineb-cell antigens; cd20; cd79a; peripheral t-cell lymphoma; rituximabCD20cd79aperipheral T-cell lymphomaB-cell antigenCD20lcsh:R5-920Chemotherapybiologybusiness.industryNot Otherwise Specifiedcd20CD79amedicine.diseaseCD79APeripheral T-cell lymphomaLymphomab-cell antigens030220 oncology & carcinogenesisbiology.proteinRituximablcsh:Medicine (General)business030215 immunologymedicine.drug
researchProduct